Whalerock Point Partners LLC grew its holdings in shares of Danaher Co. (NYSE:DHR) by 79.5% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 11,734 shares of the conglomerate’s stock after purchasing an additional 5,197 shares during the period. Whalerock Point Partners LLC’s holdings in Danaher were worth $1,089,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also added to or reduced their stakes in the business. National Asset Management Inc. grew its stake in Danaher by 0.4% during the second quarter. National Asset Management Inc. now owns 3,767 shares of the conglomerate’s stock worth $318,000 after buying an additional 14 shares during the period. Brighton Jones LLC grew its stake in Danaher by 0.4% during the second quarter. Brighton Jones LLC now owns 5,159 shares of the conglomerate’s stock worth $435,000 after buying an additional 21 shares during the period. Buckingham Asset Management LLC grew its stake in Danaher by 0.4% during the second quarter. Buckingham Asset Management LLC now owns 5,778 shares of the conglomerate’s stock worth $488,000 after buying an additional 24 shares during the period. Simmons Bank grew its stake in Danaher by 0.4% during the second quarter. Simmons Bank now owns 7,160 shares of the conglomerate’s stock worth $604,000 after buying an additional 26 shares during the period. Finally, Horizon Investments LLC grew its stake in Danaher by 0.4% during the second quarter. Horizon Investments LLC now owns 7,828 shares of the conglomerate’s stock worth $648,000 after buying an additional 28 shares during the period. Institutional investors own 76.11% of the company’s stock.
Several research firms have issued reports on DHR. Robert W. Baird reiterated a “buy” rating on shares of Danaher in a research note on Friday. Zacks Investment Research downgraded shares of Danaher from a “buy” rating to a “hold” rating in a research note on Tuesday, December 19th. Credit Suisse Group reiterated a “hold” rating and set a $99.00 price objective on shares of Danaher in a research note on Tuesday, December 19th. Royal Bank of Canada reissued a “hold” rating and set a $96.00 target price on shares of Danaher in a research report on Thursday, January 4th. Finally, Evercore ISI started coverage on shares of Danaher in a research report on Wednesday, January 3rd. They set an “outperform” rating on the stock. One analyst has rated the stock with a sell rating, six have issued a hold rating, ten have given a buy rating and one has given a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus target price of $94.91.
Danaher Co. (NYSE DHR) traded up $0.80 during midday trading on Tuesday, hitting $99.39. 1,894,500 shares of the stock were exchanged, compared to its average volume of 2,517,444. Danaher Co. has a twelve month low of $78.97 and a twelve month high of $99.66. The company has a current ratio of 1.43, a quick ratio of 1.00 and a debt-to-equity ratio of 0.42. The firm has a market capitalization of $69,140.00, a PE ratio of 29.58, a P/E/G ratio of 2.15 and a beta of 1.03.
Danaher (NYSE:DHR) last posted its earnings results on Thursday, October 19th. The conglomerate reported $1.00 EPS for the quarter, topping analysts’ consensus estimates of $0.95 by $0.05. Danaher had a net margin of 13.36% and a return on equity of 11.29%. The business had revenue of $4.53 billion for the quarter, compared to analysts’ expectations of $4.47 billion. During the same period in the previous year, the company posted $0.87 earnings per share. The business’s revenue for the quarter was up 9.6% compared to the same quarter last year. equities analysts forecast that Danaher Co. will post 3.99 earnings per share for the current fiscal year.
The business also recently declared a quarterly dividend, which will be paid on Friday, January 26th. Investors of record on Friday, December 29th will be issued a $0.14 dividend. The ex-dividend date of this dividend is Thursday, December 28th. This represents a $0.56 annualized dividend and a yield of 0.56%. Danaher’s dividend payout ratio is presently 16.67%.
In related news, CAO Robert S. Lutz sold 11,189 shares of the company’s stock in a transaction on Monday, October 23rd. The shares were sold at an average price of $91.66, for a total value of $1,025,583.74. Following the sale, the chief accounting officer now directly owns 18,314 shares of the company’s stock, valued at $1,678,661.24. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Thomas Patrick Joyce, Jr. sold 125,989 shares of the company’s stock in a transaction on Wednesday, November 1st. The shares were sold at an average price of $92.64, for a total transaction of $11,671,620.96. Following the completion of the sale, the chief executive officer now directly owns 271,737 shares in the company, valued at $25,173,715.68. The disclosure for this sale can be found here. Insiders sold 273,810 shares of company stock worth $25,218,813 over the last ninety days. 12.20% of the stock is currently owned by corporate insiders.
COPYRIGHT VIOLATION NOTICE: “Whalerock Point Partners LLC Grows Holdings in Danaher Co. (DHR)” was first published by Transcript Daily and is the property of of Transcript Daily. If you are accessing this story on another site, it was stolen and reposted in violation of US & international trademark and copyright law. The original version of this story can be read at https://transcriptdaily.com/2018/01/16/whalerock-point-partners-llc-grows-holdings-in-danaher-co-dhr.html.
Danaher Corporation (Danaher) designs, manufactures and markets professional, medical, industrial and commercial products and services. The Company operates through four segments: Life Sciences, which offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies and test new drugs and vaccines; Diagnostics; which offers analytical instruments, reagents, consumables, software and services; Dental, which provides products that are used to diagnose, treat and prevent disease and ailments of the teeth, gums and supporting bone, and Environmental & Applied Solutions, which consists of various lines of business, including water quality and product identification.
Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Co. (NYSE:DHR).
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.